Influence of end groups on in vitro release and biological activity of lysozyme from a phase-sensitive smart polymer-based in situ gel forming controlled release drug delivery system

International Journal of Pharmaceutics

Volumn 342, Issue 1-2, 2007, Pages 72-77

  Chhabra, Sumit ^a   Sachdeva, Vishal ^a   Singh, Somnath ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

End groups; Lysozyme; Phase sensitive; Smart polymer

Indexed keywords

CARBOXYLIC ACID; LYSOZYME; POLYMER;

ABSORPTION; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; IN VITRO STUDY; MICROCOCCUS LUTEUS; PRIORITY JOURNAL; SOLUBILITY;

ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DATA INTERPRETATION, STATISTICAL; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; GELS; LACTIC ACID; MICROCOCCUS; MURAMIDASE; POLYGLYCOLIC ACID; POLYMERS; SOLUTIONS; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 34547903924     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.04.034     Document Type: Article

References (31)

1. Al-Tahami K., Meyer A., and Singh J. Poly lactic acid based injectable delivery systems for controlled release of a model protein, lysozyme. Pharm. Dev. Technol. 11 (2006) 79-86
2. Brodbeck K.J., DesNoyer J.R., and McHugh A.J. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J. Control. Rel. 62 (1999) 333-344
3. Blanco D., and Alonso M.J. Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants. Eur. J. Pharm. Biopharm. 45 (1998) 285-294
4. Brodbeck K.J., Pushpala S., and McHugh A.J. Sustained release of human growth hormone from PLGA solution depots. Pharm. Res. 16 (1999) 1825-1829
5. Chandrashekhar, B.L., Madril, D., Tow, K., Balliu, C., Bawa, R.S., 2001. Sustained release of leuprolide acetate from an in-situ forming biodegradable polymeric implant as the delivery vehicle. Proceed. Int. Symp. Control. Rel. Bioact. Mater. 28, 6406.
6. Chen S., and Singh J. Controlled delivery of testosterone from smart polymer solution based systems: in vitro evaluation. Int. J. Pharm. 295 (2005) 183-190
7. Chen S., and Singh J. In vitro release of levonorgestrel from phase sensitive and thermosensitive smart polymer delivery systems. Pharm. Dev. Technol. 10 (2005) 319-325
8. Cleland J.L., Daugherty A., and Mrsny R. Emerging protein delivery methods. Curr. Opin. Biotechnol. 12 (2001) 212-219
9. Duan Y., Sun X., Gong T., Wang Q., and Zhang Z. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo. J. Mater. Sci. Mater. Med. 17 (2006) 509-516
10. Duenas, E., Okumu, F., Daugherty, A., Cleland, J.L., 2001. Sustained delivery of rhVEGF from a novel injectable liquid, PLAD. Proceed. Int. Symp. Control. Rel. Bioact. Mater. 28, 6216.
11. Eliaz R.E., and Kost J. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J. Biomed. Mater. Res. 50 (2000) 388-396
12. Eliaz R.E., and Kost J. Applications of injectable polymeric implants for protein and DNA delivery. Israel J. Chem. 45 (2005) 437-444
13. Gao P., Ding P., Xu H., Yuan Z., Chen D., Wei J., and Chen D. In vitro and in vivo characterization of huperzine a loaded microspheres made from end-group uncapped poly(d,l-lactide acid) and poly(d,l-lactide-co-glycolide acid). Chem. Pharm. Bull. 54 (2006) 89-93
14. Gong K., Darr J.A., and Rehman I.U. Supercritical fluid assisted impregnation of indomethacin into chitosan thermosets for controlled release applications. Int. J. Pharm. 315 (2006) 93-98
15. Graham P.D., Brodbeck K.J., and McHugh A.J. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Control. Rel. 58 (1999) 233-245
16. Hatefi A., and Amsden B. Biodegradable injectable in situ forming drug delivery systems. J. Control. Rel. 80 (2002) 9-28
17. Hayton W.L., and Chen T. Correction of perfusate concentration for sample removal. J. Pharm. Sci. 71 (1982) 820-821
18. Ito H., England W.P., and Lundmark S.B. Effects of polymer end groups on chemical amplification. Proc. SPIE 1672 (1992) 2-14
19. Jalbert C., Koberstein J.T., Hariharan A., and Kumar S.K. End group effects on surface properties of polymers: semiempirical calculations and comparison to experimental surface tensions for α, ω-functional poly(dimethylsiloxanes). Macromolecules 30 (1997) 4481-4490
20. Lee H.J. Protein drug oral delivery: the recent progress. Arch. Pharm. Res. 25 (2002) 572-584
21. Luan X., and Bodmeier R. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. J. Control. Rel. 10 (2006) 266-272
22. Merck Index, 2001. 13th ed., Merck & Co., Inc., Whitehouse, NJ, p. 1132.
23. Okumu, F.W., Daugherty, A., Dao, L., Filder, P.J., Brooks, D., Sane, S., Cleland, J.L., 2001. Sustained delivery of growth hormone from a novel injectable liquid, PLAD. Proceed. Int. Symp. Control. Rel. Bioact. Mater. 28, 6210.
24. Ravivarapu H.B., Moyer K.L., and Dunn R.L. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int. J. Pharm. 194 (2000) 181-191
25. Ravivarapu, H.B., Moyer, K.L. Dunn, R.L., 2000b. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS Pharm. Sci. Techol. 1 (article-1).
26. Robinson S.N., and Talmadge J.E. Sustained release of growth factors. In Vivo 16 (2002) 535-540
27. Shugar D. The measurement of lysozyme activity and the ultra-violet inactivation of lysozyme. Biochim. Biophys. Acta 8 (1952) 302-309
28. Singh S., and Singh J. Controlled release of a model protein lysozyme from phase sensitive smart polymer systems. Int. J. Pharm. 271 (2004) 189-196
29. Wang L., Kleiner L., and Venkatraman S. Structure formation in injectable poly (lactide-co-glycolide) depots. J. Control. Rel. 90 (2003) 345-354
30. Wang X., Venkatraman S.S., Boey F.Y., Loo J.S., and Tan L.P. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials 27 (2006) 5588-5595
31. Ward, R.S., White, K.A., 1996. Surface-Modifying End Groups for Biomedical Polymers. US Patent 5,589,563.